We aim to achieve the clinical application of the iPS cell-derived cardiomyocyte sheet, through joint research with Osaka University, and our alliance with Daiichi Sankyo and other partner companies, leveraging Osaka University’s research achievements pertaining to the iPS cell-derived cardiomyocyte sheet, as well as much know-how concerning drug commercialization and the preparation of the iPS cell-derived cardiomyocyte sheet that Daiichi Sankyo Co., Ltd possesses.

University/Research Institute

Osaka University, Graduate School of Medicine, Cardiovascular Surgery.

Company

Daiichi Sankyo Co., Ltd., Terumo Corp., and Mitsubishi Corp.